VEGFA and diabetic kidney disease: Strikingly, although the network pharmacology predicted that the biological processes of dapagliflozin and vildagliptin on DKD were the lipid metabolism and insulin secretion signaling pathways, the parental genes of DEcircRNAs showed that dapagliflozin biological processes were involved in the Rap1 and transcription regulation in endoplasmic reticulum pathways, while those for vildagliptin were mainly involved in the HIF-1 and VEGF signaling pathways.